Regenerative Medicine: Can Living Cells and Gene Therapy Change the World?
04 Dec, 2015, 15:37 GMT
Frost & Sullivan will participate in the panel discussion on new regenerative cell-gene therapy at the 2015 World Stem Cell Summit - RegMed Capital Conference
MOUNTAIN VIEW, California, Dec. 4, 2015 /PRNewswire/ --
| WHAT: |
Introduction to "Living" Drugs and the Curative Industries |
| WHEN: |
9:30 – 10:30 a.m. EST on Thursday, Dec. 10, 2015 |
| WHERE: |
The 2015 World Stem Cell Summit - RegMed Capital Conference at the Hyatt Regency in Atlanta, Georgia |
| PANELISTS: |
Jane C. Andrews, PhD, Senior Consultant Frost & Sullivan |
| Gregory A. Bonfiglio, Partner, Proteus Venture Partners |
|
| Robert E. Margolin, MBS, MBA, Cognate BioServices, Inc. |
|
| Chris Mason, MBBS, PhD, FRCS, University College London |
Logo - http://photos.prnewswire.com/prnh/20151204/293263LOGO
Regenerative medicine is experiencing several dynamic advancements that show great promise in curing what are now incurable diseases. A patient's cells can be removed, genetically modified to increase their ability to fight disease and subsequently placed back into the patient where they act as "living drugs". Clinical trials for such living drugs are showing 40 to 90 percent of the patients treated are cured of cancer.
Due to the curative potential and innovative opportunities provided by living drugs, companies such as Novartis, Juno Therapeutics and Kite Pharmaceuticals are racing to commercialize living cell therapies and drugs that are capable of fighting diseases such as Lymphoma and Leukemia.
Although these cell-gene therapies are showing great potential in their ability to cure disease, commercially producing them will be challenging.
The challenge is due, in part, to the following issues:
- The inherent variability of living systems
- The immunological barrier between recipients
- The cost of product production
One product must be created for each patient and each batch must be tested to insure quality and low variability. The cost of goods sold for each product can be as high as $150,000 to $200,000, resulting in patient out-of-pocket expenses ranging from $300,000 to $450,000 per treatment, which is not covered by insurance.
Attend this panel to discover:
- The obstacles living drugs are facing
- What living drugs are and the impact they will have on society
- Where the industry is going and the difference it will make in medicine
Registration
To attend this panel or for more information about the 2015 World Stem Cell Summit, visit: http://bit.ly/1HAezDF.
Thought leader insights:
"New advancements in molecular and cellular biology as well as gene therapy are being integrated to create "living drugs" said Frost & Sullivan's Transformational Health Senior Consultant, Jane C. Andrews, Ph.D. "This approach is adding a new dimension to regenerative medicine in which once incurable diseases may soon be effectively treated."
Supporting Resources
For more information about Frost & Sullivan's global Healthcare practice, please visit: http://www.healthcare.frost.com.
About World Stem Cell Summit
The World Stem Cell Summit, produced by the Genetics Policy Institute (GPI), is the largest interdisciplinary, networking meeting of stem cell science and regenerative medicine stakeholders, uniting the diverse community. With the overarching purpose of fostering biomedical research, funding and investments targeting cures, the Summit is the single conference charting the future of this burgeoning field.
The program provides the research, industry, economic and societal context for understanding how all of the pieces of the stem cell science and regenerative medicine puzzle fit together. Supported by 200 organizing partners, sponsors, exhibitors, endorsing organizations and media partners, the Summit is a three-day showcase of innovation, insight and inspiration.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact:
Kayla Belcher
Corporate Communications - North America
+1.210.247.2450
kayla.belcher@frost.com
Related Links
SOURCE Frost & Sullivan